GlassScriptPhysician profile
Ashley Jessup
NPI 1306257332
$1,954.99
in general payments reported to CMS, 2019-2025
27 companies · $180 in 2025
The $180 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $205 · 2020: $346 · 2021: $358 · 2022: $203 · 2023: $465 · 2024: $199 · 2025: $180.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $827 · Education: $17.80.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $826.73 |
| Education | $17.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $273.91 | 2019-2024 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $235.00 | 2019-2024 | Mounjaro, Zepbound |
| Pfizer INC. | $219.10 | 2019-2023 | |
| Xeris Pharmaceuticals, INC. | $194.39 | 2022-2025 | Gvoke Hypopen |
| Abbvie INC. | $188.80 | 2021-2023 | |
| Otsuka America Pharmaceutical, INC. | $131.12 | 2023-2025 | Rexulti, Abilify Maintena |
| Boehringer Ingelheim Pharmaceuticals, INC. | $104.16 | 2020-2022 | |
| Ironshore Pharmaceuticals INC. | $81.30 | 2021-2024 | Jornay Pm |
| Amgen INC. | $73.47 | 2019-2021 | |
| Exact Sciences Corporation | $49.06 | 2023-2025 | Cologuard Collection Kit |
| Amarin Pharma, INC. | $44.56 | 2020-2021 | |
| Genentech USA, INC. | $39.57 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $32.22 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $30.96 | 2024 | Airsupra, Breztri |
| Medtronic, INC. | $27.98 | 2025 | Inceptiv |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $25.27 | 2024 | |
| Dexcom, INC. | $23.89 | 2025 | Dexcom G6 Transmitter |
| Corium, LLC | $21.77 | 2022 | |
| Astellas Pharma US INC | $19.84 | 2019 | |
| Ascendis Pharma Endocrinology INC | $19.41 | 2024 | |
| Aucta Pharmaceuticals, INC. | $19.01 | 2025 | Motpoly Xr |
| Supernus Pharmaceuticals, INC. | $18.73 | 2023 | Qelbree |
| Shire North American Group INC | $18.47 | 2019 | |
| Janssen Pharmaceuticals, INC | $17.75 | 2020 | |
| Merck Sharp & Dohme LLC | $16.27 | 2021 | |
| Inspire Medical Systems, INC. | $14.95 | 2024 | Inspire |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.03 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Jessup listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.